{"id":127087,"date":"2025-11-11T07:30:07","date_gmt":"2025-11-11T07:30:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/127087\/"},"modified":"2025-11-11T07:30:07","modified_gmt":"2025-11-11T07:30:07","slug":"microvascular-complications-of-type-2-diabetes-with-or-without-masld-the-epsomip-study-a-primary-care-cohort-study-bmc-primary-care","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/127087\/","title":{"rendered":"Microvascular complications of type 2 diabetes with or without MASLD: the EPSOMIP study, a primary care cohort study | BMC Primary Care"},"content":{"rendered":"

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 2018;16(1):130.<\/p>\n

PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Patel PJ, Banh X, Horsfall LU, Hayward KL, Hossain F, Johnson T, et al. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J. 2018;48(2):144\u201351.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Polanco-Briceno S, Glass D, Stuntz M, Caze A. Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists. BMC Res Notes. 2016;9:157.<\/p>\n

PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

van Asten M, Verhaegh P, Koek G, Verbeek J. The increasing burden of NAFLD fibrosis in the general population: time to bridge the gap between hepatologists and primary care. Hepatology. 2017;65(3):1078.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bergram M, Nasr P, Iredahl F, Kechagias S, R\u00e5dholm K, Ekstedt M. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish primary health care. Scand J Gastroenterol. 2021;(1):10. https:\/\/doi.org\/10.1080\/00365521.2021.1984572<\/a>.<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56(3):943\u201351.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Nationella Diabetesregistret \u00e5rsrapport. 2023: The Swedish National Diabetes Register; 2024. Available from: https:\/\/ndr.registercentrum.se<\/a>. Accessed 2025-10-15.<\/p>\n

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917\u201323.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936\u201344.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F. Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11040968<\/a>.<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mikolasevic I, Rahelic D, Turk-Wensween T, Ruzic A, Domislovic V, Hauser G, et al. Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: a multicenter study. Diabetes Res Clin Pract. 2021;177:108884.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Song D, Li C, Wang Z, Zhao Y, Shen B, Zhao W. Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: a meta-analysis of observational studies. J Diabetes Investig. 2021;12(8):1471\u20139.<\/p>\n

PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Afarideh M, Aryan Z, Ghajar A, Ganji M, Ghaemi F, Saadat M, et al. Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes. Prim Care Diabetes. 2019;13(6):505\u201314.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

de L\u00e9dinghen V, Vergniol J, Gonzalez C, Foucher J, Maury E, Chemineau L, et al. Screening for liver fibrosis by using FibroScan(\u00ae) and fibrotest in patients with diabetes. Dig Liver Dis. 2012;44(5):413\u20138.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhang L, Lin Y, Huang X, Zhai Z, Wei R, Mo J, et al. Metabolic dysfunction-associated fatty liver disease in the elderly with diabetic foot ulcers: a longitudinal cohort study. Int Wound J. 2024;21(4):e14586.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Huang X, Li Z, Zhai Z, Wang Q, Wei R, Mo J, et al. Association between metabolic Dysfunction-Associated fatty liver disease and MACCEs in patients with diabetic foot ulcers: an ambispective longitudinal cohort study. Diabetes Metab Syndr Obes. 2024;17:1119\u201330.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156\u201362.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64\u201376.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65(5):1006\u201316.<\/p>\n

PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Definition. and Diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation. Geneva, Switzerland: World Health Organization; 2006.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

WHO Guidelines Approved by the Guidelines Review Committee. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva: World Health Organization. Copyright \u00a9 World Health Organization 2011.; 2011.<\/p>\n

Nasr P, Iredahl F, Dahlstr\u00f6m N, R\u00e5dholm K, Henriksson P, Cedersund G, et al. Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterol. 2021;21(1):180.<\/p>\n

PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gastroenterology SSo. Nationell riktlinje – Utredning och handl\u00e4ggning av fettleversjukdom 2020 [Swedish guidelines for NAFLD]. Available from: https:\/\/svenskgastroenterologi.se\/wp-content\/uploads\/2020\/02\/2020-utredning-och-handlaggning-av-fettleversjukdom.pdf<\/a>. Accessed 2025-10-15.<\/p>\n

Bedossa P. Utility and appropriateness of the fatty liver Inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565\u201375.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u201321.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

EASL-EASD-EASO Clinical. Practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Skinner HA, Sheu WJ. Reliability of alcohol use indices. The lifetime drinking history and the MAST. J Stud Alcohol. 1982;43(11):1157\u201370.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789\u201395.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders D, et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology. 2013;57(6):2180\u20138.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67(6):2089\u2013100.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677\u201382.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Shen TH, Wu CH, Lee YW, Chang CC. Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12\u201379 years. Eur J Gastroenterol Hepatol. 2024;36(5):636\u201345.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Nanayakkara N, Ranasinha S, Gadowski A, Heritier S, Flack JR, Wischer N, et al. Age, age at diagnosis and diabetes duration are all associated with vascular complications in type 2 diabetes. J Diabetes Complications. 2018;32(3):279\u201390.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Miller KC, Geyer B, Alexopoulos AS, Moylan CA, Pagidipati N. Disparities in metabolic dysfunction-associated steatotic liver disease prevalence, diagnosis, treatment, and outcomes: a narrative review. Dig Dis Sci. 2025;70(1):154\u201367.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Singh SS, van Roeters-Lennep JE, Lemmers RFH, van Herpt TTW, Lieverse AG, Sijbrands EJG. Sex difference in the incidence of microvascular complications in patients with type 2 diabetes mellitus: a prospective cohort study. Acta Diabetol. 2020;57(6):725\u201332.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mart\u00ednez-S\u00e1nchez FD, Corredor-Nassar MJ, Feria-Agudelo SM, Paz-Zarza VM, Martinez-Perez C, Diaz-Jarquin A, et al. Factors associated with advanced liver fibrosis in a population with type 2 diabetes: a multicentric study in Mexico City. J Clin Exp Hepatol. 2025;15(4):102536.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Yang K, Lee J, Han JW, Yang H, Chae SY, Chung BS, et al. A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases. Ther Adv Gastroenterol. 2025;18:17562848251331315.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Park SK, Kim MH, Jung JY, Oh CM, Ha E, Nam DJ, et al. Changes in smoking status, amount of smoking and their relation to the risk of microvascular complications in men with diabetes mellitus. Diabetes Metab Res Rev. 2023;39(8):e3697.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Balkhed W, Bergram M, Iredahl F, Holmberg M, Edin C, Carlh\u00e4ll CJ, et al. Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care. J Intern Med. 2025. https:\/\/doi.org\/10.1111\/joim.20103<\/a>.<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gao S, Zhang H, Long C, Xing Z. Association between obesity and microvascular diseases in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2021;12:719515.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gao Z, Deng H, Qin B, Bai L, Li J, Zhang J. Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease. Front Med. 2025;12:1539283.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013;128(12):1325\u201334.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Ma XM, Guo YM, Jiang SY, Li KX, Zheng YF, Guo XG, et al. Potential predictive role of non-HDL to HDL cholesterol ratio (NHHR) in MASLD: focus on obese and type 2 diabetic populations. BMC Gastroenterol. 2025;25(1):79.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Han M, Shen Y, Guo X, Hong C, Ji X, Guo H, et al. Association between non-high-density lipoprotein cholesterol and type 2 diabetes: a systematic review and meta-analysis of cohort studies. Endocr J. 2025;72(1):43\u201351.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Baek SU, Yoon JH, High-Sensitivity C-R. Protein levels in metabolic dysfunction-Associated steatotic liver disease (MASLD), metabolic Alcohol-Associated liver disease (MetALD), and alcoholic liver disease (ALD) with metabolic dysfunction. Biomolecules. 2024;14(11):1486.<\/p>\n

Tang M, Cao H, Wei XH, Zhen Q, Liu F, Wang YF, et al. Association between high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:885516.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Vaz J, Nasr P, Helander A, Shang Y, Wester A, Strandberg R, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.019<\/a>.<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Elgendy R, Desch\u00eanes SS, Burns RJ, Levy M, Schmitz N. Alcohol consumption, depressive symptoms, and the incidence of diabetes-related complications. J Diabetes. 2019;11(1):14\u201322.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Perazza F, Leoni L, Colosimo S, Musio A, Bocedi G, D\u2019Avino M, et al. Metformin and the liver: unlocking the full therapeutic potential. Metabolites. 2024. https:\/\/doi.org\/10.3390\/metabo14040186<\/a>.<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bahardoust M, Mehrabi Y, Hadaegh F, Azizi F, Khalili D, Delpisheh A. The association between duration of Metformin and sulfonylurea treatment and microvascular complications in patients with incident type 2 diabetes: a pooled cohort analysis. J Diabetes Metab Disord. 2025;24(1):94.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang MW, Lu LG. Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a clinical perspective. J Clin Transl Hepatol. 2025;13(1):47\u201361.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(10):933\u201341.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jingi AM, Noubiap JJ, Essouma M, Bigna JJ, Nansseu JR, Ellong A, et al. Association of insulin treatment versus oral hypoglycaemic agents with diabetic retinopathy and its severity in type 2 diabetes patients in Cameroon, sub-Saharan Africa. Ann Transl Med. 2016;4(20):395.<\/p>\n

PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Yan LH, Mu B, Guan Y, Liu X, Zhao N, Pan D, et al. Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications. J Diabetes Investig. 2016;7(6):889\u201394.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Adrian T, Hornum M, Knop FK, Almdal T, Rossing P. Nonalcoholic fatty liver disease in patients with type 2 diabetes and chronic kidney disease. Nephron. 2023;147(6):317\u201328.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Papagianni M, Sofogianni A, Tziomalos K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol. 2015;7(4):638\u201348.<\/p>\n

PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Williams KH, Burns K, Constantino M, Shackel NA, Prakoso E, Wong J, et al. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. J Diabetes Complications. 2015;29(8):1240\u20137.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kim K, Oh TJ, Cho HC, Lee YK, Ahn CH, Koo BK, et al. Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes. Sci Rep. 2021;11(1):24372.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

K\u00e4r\u00e4j\u00e4m\u00e4ki AJ, Hukkanen J, Ukkola O. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review. Ann Med. 2018;50(5):371\u201380.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471\u20138.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Forlano R, Stanic T, Jayawardana S, Mullish BH, Yee M, Mossialos E, et al. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int. 2024;44(1):61\u201371.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31(5):700\u20136.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care. 2015;38(7):1347\u201355.<\/p>\n

PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, et al. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 2015;3:141\u20135.<\/p>\n

PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

National Board of Health and Welfare. Nationella riktlinjer f\u00f6r diabetesv\u00e5rd [Swedish guidelines for diabetes 2018]. Available from: https:\/\/www.socialstyrelsen.se\/publikationer\/nationella-riktlinjer-for-diabetesvard–stod-for-styrning-och-ledning-2018-10-25\/<\/a>.\u00a0Accessed 2025-10-15.<\/p>\n

Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S, et al. Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol. 2025;23(1):103\u201313.<\/p>\n

CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n","protected":false},"excerpt":{"rendered":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic…\n","protected":false},"author":2,"featured_media":127088,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[80140,47708,163,85,46,80142,11395,80139,4214,47709,10396,80141],"class_list":["post-127087","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-diabetes-complications","tag-general-practice-family-medicine","tag-health","tag-il","tag-israel","tag-liver-biopsy","tag-magnetic-resonance-imaging","tag-masld","tag-primary-care","tag-primary-care-medicine","tag-type-2-diabetes","tag-vibration-controlled-transient-elastography"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/127087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=127087"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/127087\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/127088"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=127087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=127087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=127087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}